Inorganic Chemical
FDA Approves Avadel’s Lumryz for Pediatric Narcolepsy Patients
Avadel Pharmaceuticals, Lumryz, narcolepsy, pediatric patients, FDA approval, sodium oxybate, cataplexy, excessive daytime sleepiness (EDS)
Gritstone’s GRANITE Vaccine Shows Encouraging but Limited Benefit in Metastatic Colorectal Cancer
Gritstone bio, GRANITE, cancer vaccine, metastatic colorectal cancer, MSS-CRC, neoantigen targeting immunotherapy, progression-free survival, ctDNA
Gritstone Bio Explores Strategic Alternatives Amid Financial Strains and Mixed Cancer Vaccine Trial Results
Gritstone Bio, GRANITE, cancer vaccine, strategic alternatives, financial challenges, Phase 2 trial results
Novo Nordisk’s GLP-1 Agonist Demonstrates Significant BMI Reduction in Children Aged 6-12 in Phase 3 Trial
GLP-1 agonists, obesity, weight loss, liraglutide, semaglutide, pediatric obesity, BMI reduction, Novo Nordisk, Phase 3 trial.
Novo Nordisk’s Saxenda Demonstrates Significant Weight Loss in Children Aged 6-12 in Phase III Trial
Saxenda, Novo Nordisk, pediatric obesity, weight loss, Phase III trial, EASD24
FDA Approves Tris Pharma’s Onyda XR, First Liquid Non-Stimulant ADHD Medication for Pediatric Patients ###
Tris Pharma, Onyda XR, ADHD, Non-stimulant, Liquid medication, Pediatric patients, FDA approval, Clonidine hydrochloride, Extended-release oral suspension, LiquiXR technology
Sands Capital Successfully Raises $555 Million for Third Life Sciences Venture Fund
Sands Capital, life sciences, venture fund, fundraising, healthcare investments, biotechnology, medical technology, pharmaceuticals, healthcare innovation.
FDA Fast-Tracks Day One’s Innovative Therapy for Pediatric Brain Tumors
FDA, accelerated approval, Day One, targeted treatment, pediatric brain tumors, glioma, children, cancer treatment, innovative therapy.
Day One Outshines Novartis: FDA Approves Ojemda for Wider Pediatric Brain Tumor Treatment
Day One, Novartis, FDA, Ojemda, pediatric brain tumor, cancer treatment, clinical trials, pharmaceutical industry.